Patient follow-up: Unclear; only 27/101 (27%) of people randomised to cognitive therapy (augmentation or switch) completed the full 16 sessions of scheduled treatment.
METHODS

Design:
Randomised controlled trial. Allocation: Unclear. Blinding: Single blind (assessors blinded). Follow-up period: 12 weeks.
MAIN RESULTS
There was no difference between augmentation with cognitive therapy and augmentation with medication in rate of remission from depression (remission rate: 23% with cognitive therapy vs 33% with medication; p = 0.1967). Augmentation with medication reduced time to remission (p = 0.022). There was no difference between switch to medication and switch to cognitive therapy in remission (remission rate: 25% with cognitive therapy vs 28% with medication; p = 0.6881). There was also no significant difference between groups in the time to remission (p = 0.9350). The number of people experiencing side effects was greater with medication switch, but discontinuation because of intolerance to treatment was not significantly different between switch arms (17% with cognitive therapy vs 27% with medication; p = 0.2330).
CONCLUSIONS
There were no appreciable differences between cognitive therapy and pharmacotherapy as second-line treatment in citalopram-resistant depression, but the study may have been underpowered to detect differences. c Additional notes are published online only at http://ebmh.bmj.com/content/vol11/ issue2 COMMENTARY T his study, one of many from STAR*D, seeks to answer questions about real world treatments and contexts. The findings-that CBT is equivalent to pharmacotherapies as a second step after non-remission with citalopram-is plausible and reassuring. A number of factors erode the study's potential for validity from a pure efficacy perspective: very few agreed to randomisation to CBT and only 25% completed the allotted 16 sessions. However, these limitations actually support the generalisability and effectiveness of the findings. For instance, the study provided medications free, but co-payments were required for CBT, and it is possible that some subjects may have had insurance plans that would have required full payment for therapy, dissuading some from opting for potential randomisation to CBT.
ABSTRACTED FROM
Patients could be switched to CBT monotherapy or could have CBT added to pharmacotherapy; those in the switch pathway were less likely to agree to CBT, as that also involved terminating treatment with the original physician who began their depression treatment. Furthermore, individuals assigned to CBT received therapy from adequately trained and monitored, but non-expert, CBT therapists who usually worked at a treatment setting different from the one where the subject saw the treating physician. Thus, what was tested was the effectiveness of what is a real world scenario: what happens when you send the patient away to see an average CBT therapist at another site? The answer is that many patients do not want to go, many do not complete treatment, but overall they do as well as if they had stayed in your office and received another pharmacotherapy. Both for the clinician and the patient, it is very helpful to know that there is true clinical equipoise about the next treatmentmedication or CBT-after failure of the first antidepressant. Furthermore, the answer is that the next treatment has about a 30% chance of hitting remission, with medication reaching that point slightly sooner.
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